Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current COVID-19 infection less than or equal to (≤)72 hours prior to randomization~* Are men or non-pregnant women~* Women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study~* Agree to the collection of nasopharyngeal swabs and venous blood~Exclusion Criteria:~* Require mechanical ventilation or anticipated impending need for mechanical ventilation~* Received convalescent COVID-19 plasma treatment prior to enrollment~* Were resident in a nursing home or long-term care facility immediately prior to current hospitalization~* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product~* Have an oxygen saturation (SpO2) less than (\<)88 percent (%) while breathing room air at rest at randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LY3819253 (Type: EXPERIMENTAL): Participants received single doses of 700 milligrams (mg), 2800 mg or 7000 mg LY3819253 administered as intravenous infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received single dose of Placebo as intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).